País: Canadá
Língua: inglês
Origem: Health Canada
FESOTERODINE FUMARATE
SANDOZ CANADA INCORPORATED
G04BD11
FESOTERODINE
4MG
TABLET (EXTENDED-RELEASE)
FESOTERODINE FUMARATE 4MG
ORAL
15G/50G
Prescription
Antimuscarinics
Active ingredient group (AIG) number: 0153091001; AHFS:
APPROVED
2021-10-26
_Sandoz Fesoterodine Fumarate (fesoterodine fumarate extended-release tablets)_ _ _ _Page 1 of 38_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr SANDOZ ® FESOTERODINE FUMARATE fesoterodine fumarate extended-release tablets Extended-release Tablets 4 mg and 8 mg Oral Anticholinergic - Antispasmodic Agent Sandoz Canada Inc. 110 de Lauzon Street Boucherville, Quebec J4B 1E6 Date of Preparation: October 25, 2021 Submission Control No: 246438 _ _ _Sandoz Fesoterodine Fumarate (fesoterodine fumarate extended-release tablets)_ _ _ _Page 2 of 38_ RECENT MAJOR LABEL CHANGES Not applicable TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics .......................................................................................................... 4 1.2 Geriatrics........................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION................................................................................. 5 4.1 Dosing Considerations ....................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment..................................................... 5 4.3 Reconstitution ................................................................................................... 5 4.4 Administration................................................................................................... 5 4.5 MISSED DOSE .............. Leia o documento completo